parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in neutrophil progenitors	0.75
chemistry Open Targets	reachable by antibody	0.36
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 28	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 15190

SLC39A11 in astrocytes, braak-0.26 (p 0.493) → +0.31 (p 0.421)receipt 15197
SLC39A11 in dopamine neurons, braak-0.20 (p 0.597) → -0.47 (p 0.202)receipt 15198

receipt 15198: SLC39A11 in dopamine neurons, braak

power: full sample -0.21 (p 0.393, n 18), 95% CI -0.62 to +0.28. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.23 (p 0.355, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.20 (p 0.424, n 18). could be the mix.
skeptic: leave-one-out range -0.39 to -0.13, sign flips 0; without severely affected donors -0.21 (p 0.393, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC39A11 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15197: SLC39A11 in astrocytes, braak

power: full sample +0.08 (p 0.754, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.10 (p 0.696, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.14 (p 0.573, n 18). could be the mix.
skeptic: leave-one-out range -0.06 to +0.20, sign flips 3; without severely affected donors +0.08 (p 0.754, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for SLC39A11 in astrocytes.

case closed: nothing better to follow up.

loading the receipts